[{"orgOrder":0,"company":"University of Miami","sponsor":"Provectus Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Rose Bengal Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Miami \/ Provectus Biopharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"University of Miami \/ Provectus Biopharmaceuticals"},{"orgOrder":0,"company":"ACTG","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dolutegravir Sodium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ACTG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ACTG \/ ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"ACTG \/ ViiV Healthcare"}]

Find Clinical Drug Pipeline Developments & Deals for Moxifloxacin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of Miami

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          University of Miami

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Details : Provectus will use the University’s PDAT medical device with RB-PDT for treating bacterial and parasitic infections of the eye.

                          Brand Name : RB-PDT

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 27, 2024

                          Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Provectus Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          ACTG

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          ACTG

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.

                          Brand Name : Tivicay

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 14, 2024

                          Lead Product(s) : Dolutegravir Sodium,Rifapentine,Moxifloxacin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : ViiV Healthcare

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank